AZN AstraZeneca Plc: Total Company Value-to-Revenue Ratio

Public company logo of AstraZeneca Plc (AZN)

AstraZeneca PLC (AZN) dominance in oncology and protection against generics ensure high margins, as confirmed by the EV/Sales history. The 4779.40 mark indicates the enterprise value-to-revenue valuation level. Its status as a global innovator guarantees physician trust, while colossal R&D expenditures and strict government regulation create insurmountable barriers to entry for new players.

AZN (AstraZeneca Corp.) Enterprise Value-to-Revenue Ratio history from 11/23/2025 to 11/20/2026

Financial and market metric breakdowns for AstraZeneca (AZN)

- current quotes and average value forecast:
Fundamental company valuation:AZN, astrazeneca.com
Mass-produced product of astrazeneca.com

This metric combines market capitalization and net debt, comparing the total cost of acquiring the business with its annual turnover. This metric allows for the determination of the market asset value multiple, adjusted for debt load, to identify undervaluation or stagnation. The efficiency of AstraZeneca PLC (AZN) plants in the US and Europe directly impacts revenue, making the EV/Sales business valuation a key indicator of operational resilience.